ArticleFrontiers in cardiovascular medicine2023
The therapeutic concordance approach reduces adverse drug reactions in patients with resistant hypertension.
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02211365 (Registro Campania Salute Network for the Treatment of Hypertension and Correlated Diseases), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Registro Campania Salute Network for the Treatment of Hypertension and Correlated Diseases
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial Intelligence in Cardiovascular Medicine: Focus on Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Pooled it
- Integrating Proteomics and Mendelian Randomization to Identify New Therapeutic Targets.American journal of hypertension · 2025Article
- Optimizing hypertension management in China: care cascade insights and individual determinants from a national survey.Current medical research and opinion · 2025Article
- Achieving a Systolic Blood Pressure Below 130 mmHg Reduces the Incidence of Cardiovascular Events in Hypertensive Patients with Echocardiographic Left Ventricular Hypertrophy.The Journal of pharmacology and experimental therapeutics · 2024Article
- Effectiveness of a nurse-led management intervention on systolic blood pressure among type 2 diabetes patients in Uganda: a cluster randomized trial.Clinical diabetes and endocrinology · 2024Article
- Article
- Prescribers' adherence to clinical practice guidelines for the management of hypertension at public hospitals in Northwest Ethiopia: An explanatory sequential mixed-methods study.Sage open chronic diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Background: Adverse drug reactions (ADRs) remain among the leading causes of therapy-resistant hypertension (TRH) and uncontrolled blood pressure (BP). We have recently reported beneficial results in BP control in patients with TRH adopting an innovative approach, defined as therapeutic concordance, in which trained physicians and pharmacists reach a concordance with patients to make them more involved in the therapeutic decision-making process. Methods: The main scope of this study was to investigate whether the therapeutic concordance approach could lead to a reduction in ADR occurrence in TRH patients. The study was performed in a large population of hypertensive subjects of the Campania Salute Network in Italy (ClinicalTrials.gov Identifier: NCT02211365). Results: We enrolled 4,943 patients who were firstly followed-up for 77.64 ± 34.44 months, allowing us to identify 564 subjects with TRH. Then, 282 of these patients agreed to participate in an investigation to test the impact of the therapeutic concordance approach on ADRs. At the end of this investigation, which had a follow-up of 91.91 ± 54.7 months, 213 patients (75.5%) remained uncontrolled while 69 patients (24.5%, Conclusion: Our findings indicate that the therapeutic concordance approach significantly reduces ADRs in TRH patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.